Rhone-Poulenc Rorer(RPR)公司的谷氨酸拮抗剂Rilutek(riluzole)已在美国首次上市,它用于治疗肌萎缩性脊髓侧索硬化(ALS,亦称运动神经元病或Lou Gehrig’s症)。 RPR公司称,Rilutek是一个能延长ALS病人生存期的药物,在美国提交新药申请后不到7个月就上市了。该公司已向欧洲等主要市场提出该药的上市申请,目前正在等候批准。 Rilutek (riluzole), a glutamate antagonist from Rhone-Poulenc Rorer (RPR), was first marketed in the United States for the treatment of amyotrophic lateral sclerosis (ALS, also known as motor neuron disease or Lou Gehrig’s disease). The RPR company said that Rilutek is a drug that prolongs the life of an ALS patient and goes public in less than seven months after the drug application was filed in the United States. The company has filed a listing application for the drug in major markets such as Europe and is awaiting approval.